Alect2 amyloidosis: primum non nocere (first, do no harm).
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 25079018.
- Also identified by DOI 10.1038/ki.2014.45.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Said et al. and Larsen et al. present the clinical, morphologic, and genetic features of a recently described amyloidosis, derived from leukocyte chemotactic factor 2 (Alect2), which is beginning to be recognized as an important cause of end-stage renal disease in Hispanics. While the etiology of Alect2 is unknown, and there is currently no effective treatment, it is important to avoid misdiagnosing it as the more common AL, and applying harmful treatment in consequence.
Medical subject headings
- Amyloidosis
- Intercellular Signaling Peptides and Proteins
- Kidney Diseases